Allogene Therapeutics, Inc.'s revenue has grown 302% a year over three years, and shrunk 29% a year over five. Revenue growth, 3-year annual rate: +302% (Biotechnology median +21%). Revenue growth, 5-year rate: −29%, growth has picked up over the last three years. Years of annual history on file: 8, FY2018 to FY2025, as filed.

ALLOAllogene Therapeutics, Inc.

Healthcare

$1.24+2.5% 1Y

$1.24

$1.0552 weeks$3.06

Is it growing?

Good

Growing: revenue growing +481% year on year and operating margin widening (+338599.9 points).

2 good, 1 without data

Revenue trend+481% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −29% a year.

Margin direction+338599.9 points operating

Trailing-twelve-month operating margin, -4811.2% now against -343411.1% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is ALLO growing?

Allogene Therapeutics, Inc.'s revenue has grown 302% a year over three years, and shrunk 29% a year over five.

+302%

Revenue growth, 3-year annual rate · Biotechnology median +21% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: −29%
Revenue growth, 5-year rate · +302% over three · growth has picked up over the last three years
Years of annual history on file: 8
Years of annual history on file · FY2018 to FY2025, as filed

Details›